Skip to main content
Premium Trial:

Request an Annual Quote

Steven Tregay

Premium
Cequent Pharmaceuticals said this week that Steven Tregay has been appointed to the company’s board of directors.
Tregay is a managing director of the Novartis Option Fund, a $200 million equity-investment fund operated by the Novartis Corporate Venture Funds. He joined Cequent’s board following an undisclosed investment in the company by the Novartis Option Fund (see related story, this issue).
 

Tregay has held several different roles with Novartis, and holds a PhD and MS in organic chemistry from Harvard University.

The Scan

Gone, But Now Reconstructed SARS-CoV-2 Genomes

In a preprint, a researcher describes his recovery of viral sequences that had been removed from a common database.

Rare Heart Inflammation Warning

The Food and Drug Administration is adding a warning about links between a rare inflammatory heart condition and two SARS-CoV-2 vaccines, Reuters reports.

Sandwich Sampling

The New York Times sent tuna sandwiches for PCR analysis.

Nature Papers Describe Gut Viruses, New Format for Storing Quantitative Genomic Data, More

In Nature this week: catalog of DNA viruses of the human gut microbiome, new dense depth data dump format to store quantitative genomic data, and more.